Nurix Therapeutics rises after U.S. FDA lifts hold on cancer study

Nurix Therapeutics

11/03/2024 13:09

** Shares of drug developer Nurix Therapeutics  NRIX.O  rise
1% to $15.02 premarket
    ** Co says that the U.S. FDA has lifted partial clinical
hold on its early-stage study testing its experimental cancer
drug
    ** The drug, NX-2127, is being developed to treat adult
patients with a type of cancer that affects the immune cells
    ** The hold was placed in November after communication to
FDA of co's intention to transition to an improved manufacturing
process
    ** NRIX to re-start enrollment for the trial and prioritize
patients with aggressive forms of non-Hodgkin's lymphoma, a type
of blood cancer
    ** Up to last close, stock has risen 63.7% in the last 12
months

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))